Drugs targeting PARP-1, such as olaparib, impair the DDR (Lord and Ashworth, 2017), and sensitize tumor cells to other treatments that cause DNA damage (Ray Chaudhuri and Nussenzweig, 2017), such as radiation therapy (McMahon et al., 2016). The gene discussed is PARP1; the disease is neoplasm.